Download the FREE ebook "Beating Myeloma: If I Knew Then What I Know Now" and arm yourself with the information about autologous stem cell transplantation, treatment options, and side effects that I wish I had known about when I began treatment.
“Increase Multiple Myeloma cell death.” Boy, doesn’t that sound great? But how???
It happens to all MMers eventually. A myeloma diagnosis resulted in induction therapy (perhaps RVd), remission, an autologous stem cell transplant, and another, hopefully, deeper remission. While research has never confirmed that ASCT provides a longer overall survival (OS), research does demonstrate that the average PFS or remission is longer with an ASCT.
But now you are coming out of remission…does this mean that you are running out of therapy options? Am I nearer to the end than the beginning? Conventional wisdom says that your next remission will be shorter than your first. Just as important, you have suffered several short, long-term and late stage side effects. You are tired of the side effects that come from chemotherapy.
So what’s a relapsed/refractory MMer to do? Your oncologist is suggesting carfilzomib but you’ve heard about the difficult toxicity and side effects of this chemotherapy regimen.
According to the two studies linked and excerpted below, CBD and curcumin act synergistically to both enhance the MM killing action of CFZ as well as reduce the toxicity of CFZ. But maybe you are wondering if either/or of these integrative therapies can interfere with the efficacy of carfilzomib.
To quote “this combination (CBD and CFZ) exerts strong anti-MM activities” and “curcumin can ameliorate carfilzomib efficacy…”
To be fair, the studies below are “in vitro” meaning they take place in a test tube. No pharmaceutical company in existance is going to test a unpatentable product like curcumin or CBD in human beings. To a large extent, myeloma patients and survivors are on their own in the latter stages of their incurable disease.
To learn more about brands, strains, other integrative and complementary myeloma therapies scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
“Herein, we also found that the CBD and THC combination is able to reduce expression of the β5i subunit as well as to act in synergy with Carfilzomib (CFZ) to increase MM cell death and inhibits cell migration. In summary, these results proved that this combination exerts strong anti-myeloma activities…
In multiple myeloma, our previous findings demonstrated that CBD reduced cell proliferation and induced necrotic cell death . In the present study, our data on THC and mainly on the THC-CBD combination as stimulatory factors of autophagic-dependent cell death in MM cell lines, support previous data regarding the efficacy of cannabinoids as anti-tumoral drugs, in different human cancer models.
For cannabinoids, different experimental data suggested that the combined administration of cannabinoids with other anti-cancer drugs, could act synergistically, to reduce tumor growth and chemoresistance...
In MM cells, the CBD and Bortezomib (BTZ) combination was found to be more effective compared with BTZ alone and to act synergistically in inducing cell death .
Herein we investigated the effect of CBD and THC in combination with CFZ, showing a synergistic effect between the three drugs, supporting the fact that combining THC-CBD with established cytotoxic agents should result in a higher level of anticancer activity compared with that of cytotoxic agents acting alone…
Therefore, a combination therapy including cannabinoids and chemotherapeutic drugs could allow the reduction of chemotherapeutical doses administered in patients, without affecting the antitumoral therapy...
“Multiple myeloma (MM) is a malignant B-cell neoplasm with accumulation of malignant plasma cells in bone marrow. Pharmacological therapy improves response frequency even if with various associated toxicities.
Herein, we investigated if combination of curcumin with carfilzomib (CFZ) can induce a better cytotoxic effect on in vitro cultured U266 cells. Cell viability data showed that curcumin significantly ameliorates CFZ cytotoxic effect.
Furthermore, curcumin alone did not affect proteasome at the tested dose, confirming the involvement of different mechanisms in the observed effects. U266 cells exposure to curcumin or carfilzomib (CFZ) increased reactive species (RS) levels, although their production did not appear further potentiated following drugs combination.
Interestingly, NF-κB nuclear accumulation was reduced by treatment with CFZ or curcumin, and was more deeply decreased in cells treated with CFZ-curcumin combinations, very likely due to the different mechanisms through which they target NF-κB.
Our results confirmed the induction of p53/p21 axis and G0/G1 cell cycle arrest in anticancer activities of both drugs, an effect more pronounced for the CFZ-curcumin tested combinations.
Furthermore, curcumin addition enhanced CFZ proapoptotic effect.
These findings evidence that curcumin can ameliorate CFZ efficacy, and lead us to hypothesize that this effect might be useful to optimize CFZ therapy in MM patients.”